PSH0 Stock Chart & Stats
€0.07
>-€0.01(-2.56%)
At close: 4:00 PM EDT
€0.07
>-€0.01(-2.56%)
Day’s Range― - ―
52-Week Range€0.05 - €0.20
Previous CloseN/A
Volume4.29K
Average Volume (3M)26.52K
Market Cap
€23.55M
Enterprise Value€56.09
Total Cash (Recent Filing)€63.33K
Total Debt (Recent Filing)€2.58M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Mar 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding377,642,520
10 Day Avg. Volume68,003
30 Day Avg. Volume26,518
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.62Price Target Upside790.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Scalable Cell-therapy PlatformThe Cell Pouch System provides a potentially reusable implant platform rather than a single-purpose therapy. If clinical and regulatory objectives are achieved, its ability to host different therapeutic cells could support multiple chronic-disease applications and broaden long-term commercial opportunity.
Losses Are ImprovingThe substantial reduction in net losses indicates lower spending or improved cost control compared with prior years. Although the company remains unprofitable, a smaller loss base can extend development capacity and make future financing requirements more manageable if progress continues.
Cash Burn Has ModeratedOperating cash outflow has declined materially from earlier periods, showing that the current development run-rate is less cash intensive than in 2023 and 2024. Sustained control of burn would preserve resources for clinical work and reduce the frequency of external funding needs.
Bears Say
No Commercial RevenueZero revenue means Sernova has not yet demonstrated commercial traction or an operating engine that funds its programs. Until approval and commercialization occur, progress depends on development execution and access to capital rather than recurring customer payments.
Negative Shareholders' EquityNegative shareholders’ equity is a material solvency weakness that reflects accumulated losses and can reduce financial resilience. It leaves less balance-sheet capacity to absorb setbacks, support development spending, or negotiate future funding on favorable terms.
Reliance On External FinancingPersistent negative operating and free cash flow shows that ongoing activities are not self-funded. Continued dependence on financing exposes the company to dilution or funding constraints, which can limit program continuity and weaken its ability to control strategic timing.
Sernova News
PSH0 FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was €0.05 and its highest was €0.20 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is €23.55M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Mar 12, 2027 which is in 175 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Sep 10, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of -€0.004 by -€0.002.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Undervalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sernova have?
Sernova has 377,642,520 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -€0.006 in its last earnings report, missing expectations of -€0.004. Following the earnings report the stock price went down -30.526%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in DE:PSH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
PSH0 Stock 12 Month Forecast
Average Price Target
€0.62
▲(790.86% Upside)
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―